Efficacy of a K <sup>+</sup> Channel Agonist, <scp>XEN1101</scp> , For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis
The K<sub>V</sub>7 potassium channel agonist XEN1101 is effective as both a prophylactic agent and as abortive therapy for management of low-K<sup>+</sup> induced weakness in murine models of HypoPP. XEN1101 is more potent than the first-generation Kv7 agonist, retigabine, in our murine models of HypoPP and is also better tolerated in patients. These improvements provide a rationale for future clinical trials of XEN1101 in HypoPP patients.
Authors
- Marbella Quiñonez (ORCID: https://orcid.org/0000-0002-0684-9705)
- Stephen C. Cannon (ORCID: https://orcid.org/0000-0001-8428-3690)
- Viktor Chanchykov
- Sharon Iype
- Fenfen Wu
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1002/mus.70159
- Primary Topic
- Ion channel regulation and function
- Type
- article
- Field-Weighted Citation Impact
- 0.00